<DOC>
	<DOCNO>NCT03015922</DOCNO>
	<brief_summary>This study recruit patient currently receive either lenalidomide pomalidomide whose disease relapse . This dose escalation study aim determine maximum tolerate dose ( MTD ) REOLYSIN® give combination lenalidomide pomalidomide . The study also investigate safety , side effect effectiveness treatment combination . Pomalidomide lenalidomide evaluate separately two separate group .</brief_summary>
	<brief_title>Viral Immunotherapy Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<criteria>Diagnosed symptomatic multiple myeloma ( accord IMWG 2014 criterion ) Evaluable disease modify IMWG criterion ( i.e . abnormal serum M protein , urinary M protein serum free light chain assay ) Currently receive either lenalidomide pomalidomide therapy , alone combination myeloma therapy , evidence serological clinical disease progression define IMWG criterion ( 2011 ) Life expectancy ≥ 3 month ECOG performance status ≤2 Required laboratory value within 14 day prior dose allocation : Absolute neutrophil count ≥ 1.0 x10^9 /L . ( growth factor support permit ) Platelet count ≥ 70 x 10^9/L . ( platelet support permit ; platelet &lt; 70 ≥ 25 acceptable bone marrow &gt; 50 % infiltrated MM ) Haemoglobin ≥ 8 g/dL . Blood support permit Serum bilirubin ≤ 2 x upper limit normal ( ULN ) ALT AST ≤ 2.5 x ULN Serum creatinine ≤ 2 x ULN Corrected calcium ≤ 2.8 mmol/l Negative HIV viral ( B C ) hepatitis test result within 14 day prior dose allocation Able give informed consent willing follow trial protocol Aged 18 year All participant must agree follow Celgene Pregnancy Prevention Programme ( PPP ) participate counsel associate : Females childbearing potential ( FCBP ) must agree utilise two reliable form contraception simultaneously practice complete abstinence least 28 day prior start trial treatment , trial least 28 day trial treatment discontinuation , even case dose interruption , must agree Celgene PPP pregnancy test timeframe Females must agree abstain breastfeed trial participation 28 day trial drug discontinuation Males must agree use latex condom sexual contact FCBP ( must practice complete abstinence ) trial , include dose interruption 28 day follow discontinuation trial even undergone successful vasectomy Males must also agree refrain donate semen sperm pomalidomide include dose interruption 28 day discontinuation trial All participant must agree refrain donate blood trial drug include dose interruption 28 day discontinuation trial Nonsecretory multiple myeloma Pregnant ( positive pregnancy test ) line Celgene Pregnancy Prevention Programme breast feed Previous antitumour therapy include experimental agent , lenalidomide pomalidomide , within 28 day start protocol treatment . Steroid therapy permit , must stop 48 hour prior cycle 1 day 1 Concurrent previous malignancy ( &lt; 12 month post end treatment ) sit , exception appropriately treat localised epithelial skin cervical cancer , incidental histologic finding prostate cancer ( TNM stage T1a 1b ) . Participants history ( ≥12 month ) tumour , remission currently therapy , may enter System corticosteroid therapy comorbidities ( i.e . medical condition multiple myeloma ) stop duration trial . Topical corticosteroid therapy exclusion criterion . Any history know hypersensitivity trial medication excipients Active symptomatic fungal , bacterial , and/or viral infection Poorly control serious medical psychiatric illness , Investigator 's opinion , likely interfere participation and/or compliance clinical trial Patients significant cardiovascular disease ( e.g . history congestive heart failure require therapy ( ≥ NYHA Class III ) , presence severe valvular heart disease , presence atrial ventricular arrhythmia require treatment , uncontrolled hypertension , history QTc abnormality ) Radiotherapy major surgery within 4 week prior registration Greater equal grade 2 neuropathy , without pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>